DaVita HealthCare Partners Inc. (NYSE:DVA) saw some unusual options trading on Friday. Stock traders bought 2,129 put options on the stock. This is an increase of 610% compared to the average daily volume of 300 put options.

Shares of DaVita HealthCare Partners (NYSE DVA) opened at $60.93 on Wednesday. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.35 and a current ratio of 1.40. DaVita HealthCare Partners has a 52 week low of $52.51 and a 52 week high of $70.16. The company has a market capitalization of $11,563.95, a price-to-earnings ratio of 17.46, a P/E/G ratio of 12.32 and a beta of 0.97.

DaVita HealthCare Partners (NYSE:DVA) last announced its quarterly earnings data on Tuesday, November 7th. The company reported $0.81 EPS for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.13). DaVita HealthCare Partners had a return on equity of 13.31% and a net margin of 3.40%. The company had revenue of $3.92 billion for the quarter, compared to analyst estimates of $3.91 billion. During the same period last year, the firm earned $0.95 earnings per share. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. analysts anticipate that DaVita HealthCare Partners will post 3.42 EPS for the current year.

DaVita HealthCare Partners announced that its Board of Directors has approved a share repurchase program on Tuesday, October 10th that authorizes the company to buyback $1.50 billion in shares. This buyback authorization authorizes the company to repurchase shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Several institutional investors have recently made changes to their positions in DVA. Pzena Investment Management LLC lifted its holdings in DaVita HealthCare Partners by 2.1% during the second quarter. Pzena Investment Management LLC now owns 3,398 shares of the company’s stock worth $220,000 after acquiring an additional 71 shares in the last quarter. Speece Thorson Capital Group Inc. lifted its holdings in DaVita HealthCare Partners by 0.5% during the second quarter. Speece Thorson Capital Group Inc. now owns 280,515 shares of the company’s stock worth $18,166,000 after acquiring an additional 1,360 shares in the last quarter. Jensen Investment Management Inc. lifted its holdings in DaVita HealthCare Partners by 24.2% during the second quarter. Jensen Investment Management Inc. now owns 9,740 shares of the company’s stock worth $631,000 after acquiring an additional 1,900 shares in the last quarter. Founders Capital Management LLC lifted its holdings in DaVita HealthCare Partners by 2.3% during the third quarter. Founders Capital Management LLC now owns 95,939 shares of the company’s stock worth $5,698,000 after acquiring an additional 2,115 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new position in DaVita HealthCare Partners during the third quarter worth about $154,000. 85.32% of the stock is owned by institutional investors and hedge funds.

Several research firms have recently commented on DVA. J P Morgan Chase & Co cut DaVita HealthCare Partners from a “neutral” rating to an “underweight” rating in a research note on Monday, October 9th. Wolfe Research raised DaVita HealthCare Partners from a “market perform” rating to an “outperform” rating in a research note on Monday, October 23rd. Royal Bank Of Canada decreased their price objective on DaVita HealthCare Partners from $64.00 to $60.00 and set a “sector perform” rating for the company in a research note on Wednesday, November 8th. Robert W. Baird reaffirmed a “hold” rating and set a $63.00 price objective on shares of DaVita HealthCare Partners in a research note on Friday, November 10th. Finally, KeyCorp reaffirmed a “hold” rating on shares of DaVita HealthCare Partners in a research note on Monday, November 13th. Four research analysts have rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $63.00.

ILLEGAL ACTIVITY NOTICE: This report was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://theolympiareport.com/2017/12/06/davita-healthcare-partners-target-of-unusually-large-options-trading-dva.html.

DaVita HealthCare Partners Company Profile

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.